Task force develops new radiation guidelines for brachytherapy

November 02, 2009

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.

The guideline was issued by a task group commissioned by the American Association of Physicists in Medicine (AAPM), and will be published in the November 2009 issue of Medical Physics.

With the widespread use of image-guided dosimetry, there is a need for developing a consensus methodology for dose prescription and reporting for prostate brachytherapy. The dosimetric parameters used for evaluating an implant are dependent on physician's delineation of the prostate, rectum, bladder and urethra on post-implant imaging such as CT. Many research groups have reported that such delineation can be quite variable.

With the intent of providing consistent and reproducible dosimetric information without increasing healthcare costs, the AAPM Task Group 137 issued new recommendations and guidelines on the timing, imaging techniques, dose planning criteria and dose evaluation parameters that should be followed in documenting each brachytherapy treatment.

"This is a timely update of the original AAPM Task Group 64 report, which was instrumental in defining the early standards of practice when brachytherapy became widespread in the treatment of prostate cancer," said Dr. Yu, who also chaired the original Task Group 64 in 1998-1999. "Sophisticated brachytherapy techniques such as real-time planning, image-guided robotic implantation and dynamic dose verification are either here or imminent. The field requires a higher level of standardization, which is exactly what Task Group 137 was commissioned to address."

Based on recent brachytherapy literature, the new AAPM Task Group report recommended guidelines for dose prescription from a physics perspective for routine patient treatment, clinical trials, and for treatment planning software developers. It continues to follow the current recommendations on using D90 and V100 as the primary quantities, with more specific guidelines on the use of the imaging modalities for post-implant evaluation and the optimum timing of the imaging for specific radionuclides. In addition, the new report encourages the use of a radiobiological model with a specific set of parameters to facilitate relative comparisons of treatment plans reported by different institutions using different loading patterns or radionuclides.
-end-


Thomas Jefferson University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.